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Abstract
Background: Pemphigus vulgaris (PV) is a severe autoimmune blistering disorder characterized
by the presence of pathogenic autoantibodies directed against desmoglein-3 (Dsg3), involving
specific DR4 and DR6 alleles in Caucasians and DQ5 allele in Asians. The development of sequence-
based predictive algorithms to identify potential Dsg3 epitopes has encountered limited success
due to the paucity of PV-associated allele-specific peptides as training data.
Results: In this work we constructed atomic models of ten PV associated, non-associated and
protective alleles. Nine previously identified stimulatory Dsg3 peptides, Dsg3 96–112, Dsg3 191–
205, Dsg3 206–220, Dsg3 252–266, Dsg3 342–356, Dsg3 380–394, Dsg3 763–777, Dsg3 810–824
and Dsg3 963–977, were docked into the binding groove of each model to analyze the structural
aspects of allele-specific binding.
Conclusion: Our docking simulations are entirely consistent with functional data obtained from
in vitro competitive binding assays and T cell proliferation studies in DR4 and DR6 PV patients. Our
findings ascertain that DRB1*0402 plays a crucial role in the selection of specific self-peptides in
DR4 PV. DRB1*0402 and DQB1*0503 do not necessarily share the same core residues, indicating
that both alleles may have different binding specificities. In addition, our results lend credence to
the hypothesis that the alleles DQB1*0201 and *0202 play a protective role by binding Dsg3
peptides with greater affinity than the susceptible alleles, allowing for efficient deletion of
autoreactive T cells.
Introduction
Major histocompatibility complex (MHC) class II mole-
cules are heterodimeric glycoproteins consisting of α and
β chains, with approximate molecular mass of 33 kDa and
28 kDa respectively. MHC class II molecules are special-
ized peptide receptors that play a critical role in initiating
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and regulating immune responses by binding peptide
fragments that are 10–30 amino acids long [1] and
present them on the surface of antigen-presenting cells for
recognition by CD4+ T cells. The class II region encodes
genes for the human leukocyte antigen (HLA) or histo-
compatibility molecules class II structural genes DP, DQ
and DR [2,3]. While specific DP, DQ or DR alleles at the
HLA class II locus have been shown to correlate with par-
ticular autoimmune diseases, a variety of confounding
factors including strong linkage disequilibrium between
the different HLA alleles, especially DR and DQ, compli-
cates the exact identification of MHC susceptibility alleles.
Pemphigus Vulgaris (PV) is a potentially life-threatening
form of autoimmune blistering skin disorder due to loss
of integrity of normal intercellular attachments within the
epidermis and mucosal epithelium. The disease is charac-
terized by the presence of pathogenic autoantibodies
directed mainly against a 130-kDa transmembrane glyco-
protein, desmoglein-3 (Dsg3) [4], within the desmo-
somes of the spinous layer of the skin. Strong association
of PV to the major histocompatibility complex class II
serotypes DR4 and DR6 have been reported in the litera-
ture [5-7] with over 95% of PV patients possessing one or
both of these alleles [7]. Direct nucleotide sequence anal-
ysis of DR4 and DR6 subtypes revealed that susceptibility
to PV is strongly linked to DRB1*0402 and DQB1*0503
molecular subtypes, respectively [7,8].
The use of computational techniques has been instrumen-
tal in advancing epitope-based vaccine research, with
much work focusing on predicting the binding specifici-
ties of peptides to MHC molecules. Sequence-based pre-
dictive systems, based on identifying patterns in peptides
with experimentally determined binding strength, are
widely used to facilitate the identification of binding pep-
tides to MHC class II molecules. Southwood et al. [9]
developed a scoring matrix for DRB1*0401 based on a
polynomial technique. Mallios [10,11] reported the
results of an iterative stepwise discriminant analysis meta-
algorithm to identify binders from non-binders for
DRB1*0101. Brusic et al. [12] applied a genetic algorithm
to discriminate binders from non-binders for
DRB1*0401. Noguchi et al. [13,14] utilized both fuzzy
neural network and hidden Markov model to predict
potential binders to DRB1*0401 and DRB1*0101. Ham-
mer et al. [15] employed a peptide side chain scanning
technique for screening peptides that interact with
DRB1*0401. Nielsen et al. [16] used a Gibbs sampling
method for discriminating DRB1*0401 specific binders
from non-binders. Karpenko et al. [17] made use of an ant
colony system to search for DRB1*0401 binding and non-
binding peptides. Doytchinova and Flower [18]
employed an additive method for predicting the binding
affinity of peptides bound to DRB1*0401, DRB1*0101
and DRB1*0701 based on the sum of the contributions of
the amino acids at each position of the bound peptide and
various interactions between them. However, despite
recent advances in sequence-based predictive techniques,
computational models for the majority of PV implicated
alleles have been lacking, mainly due to the paucity of suf-
ficient peptides as training data, and are unsuitable for
predicting peptide binding to PV implicated alleles. Also,
most computational methods focus on predicting just
peptide binders and non-binders, whereas our aim is to
distinguish between different modes of binding conferred
by susceptible and protective alleles.
An alternative approach to predicting peptide/MHC
(pMHC) complexes without the need of a large training
dataset is to use information derived from three-dimen-
sional structures. Logean and Rognan [19] utilized a com-
binatorial built-up algorithm to construct the three-
dimensional structure of pMHC complexes. Altuvia et al.
[20] reported the use of a computational threading
approach to rank potentially binding peptides to MHC
class I molecules. Lim et al. [21] employed molecular
dynamic simulations to examine the structures of A*0201
in complex with 9-mer peptides. Michielin et al. [22,23]
applied homology modeling to select peptides that bind
to A*0201.
In addition to predicting the binding specificities of pep-
tides to MHC molecules, three-dimensional models have
also been used for structural classification of alleles into
HLA "supertypes" based on structural features derived
from the binding sites. Recently, Doytchinova et al.
[24,25] employed hierarchical clustering and principal
component analysis to classify alleles based on structural
features into eight HLA class I and twelve HLA class II
supertypes. The structural classification of alleles facili-
tates the identification of allelic subgroups that may share
similar binding specificities and shed light into their pos-
sible role in cellular immunity against pathogens.
In the present study, we have attempted to understand the
functional correlation between MHC class II alleles and
PV, from a structural interaction view point. Molecular
modeling of ten PV associated and non-associated MHC
class II receptors (DR4: DRB1*0401, *0402, *0404,
*0406, DR6 (also classified now as DR14): DRB1*1401,
*1404, *1405, DQ2: DQB1*0201, *0202 and DQ5:
DQB1*0503) were performed to explore the structural
organization of the binding groove of these alleles. Nine
previously identified epitopes, Dsg3 96–112, Dsg3 191–
205, Dsg3 206–220, Dsg3 252–266, Dsg3 342–356, Dsg3
380–394, Dsg3 763–777, Dsg3 810–824 and Dsg3 963–
977 (numbered in accordance with Swiss-Prot [26] acces-
sion number P32926), capable of stimulating patient
derived T cells, were selected. The binding of these pep-Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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tides to the DR and DQ structural models were studied by
our efficient computational docking protocol [27]. In the
light shed by these atomic models, the binding specifici-
ties of each allele to the various Dsg3 peptides are dis-
cussed. The results obtained in the study are able to
discriminate between PV associated and non-associated
alleles, consistent with the experimental results obtained
by Veldman et al. [28] and Sinha et al. [unpublished
results for Dsg3 342–356, 810–824 and 963–977].
Insights into structural features behind the immune
response provided by protective alleles for PV have also
been obtained by our structural immunoinformatics
approach.
Results and discussion
Allele comparisons – HLA DR4 PV
The sequence identity between the DR4 alleles (excluding
DRB1*0401) with their corresponding templates ranges
from 97.9 to 99.0%, and the sequence similarity (repre-
senting identical and conservatively substituted residues)
was between 98.4 and 99.5% (Table 1). All five important
peptide-binding pockets 1, 4, 6, 7 and 9 show extremely
high structural conservation at the Cα positions, suggest-
ing that any peptide discrimination leading to epitope
selection between the alleles is mainly due to the size and
nature of the side chains of the pocket residues. In order
to further isolate the true disease-relevant allele within a
haplotype, we compared specific residues in the polymor-
phic pockets regarded as important in conferring specifi-
city for antigen presentation (Figure 1). Pocket 1,
characterized by a Val/Gly β86 dimorphism, is the deepest
cavity and thus, the most important anchor for peptide
binding [29]. In addition, the functional specificity of
DR4 molecules is also affected by polymorphisms at posi-
tion β70, β71, β74, which contribute to pocket 4. Two
negatively charged residues at position β70 and β71 that
were previously suggested to influence peptide selectivity
in PV patients [30] could be found in DRB1*0402 (Asp
β70 and Glu β71) but a positively charge Arg/Lys β71 was
found in DRB1*0404, *0406 and *0401. Amino acid pol-
ymorphism can also be observed at position β11 of
pocket 6, β71 of pocket 7 and β37 of pocket 9 respectively.
Allele comparisons – HLA DR6 PV
Study of individual allele frequencies in DR6 PV patients
revealed that the relevant disease susceptibility allele is
DQB1*0503 instead of DR6 alleles [Sinha et al., manu-
script in preparation]. DQB1*0503 and the DR6 PV non-
associated alleles investigated in this study show a signifi-
cant degree of overlap in alignment, with 14 amino acid
differences in areas of the binding cleft that could affect
peptide binding. Clear differences in the amino acid
sequences are observed at residue β86 of pocket 1, resi-
dues β13, β70, β71, β74, β78 of pocket 4, residue β11 of
pocket 6, residues β28, β30, β67, β71 of pocket 7 and res-
idues β9, β37, β57, β60 of pocket 9. Similar to the DR4
alleles, all five important peptide-binding pockets 1, 4, 6,
7 and 9 in DBQ1*0503 and DR6 alleles demonstrate
exceptionally high structural conservation at the Cα posi-
tions. A significant difference is that DQB1*0503 contains
a negatively charged Asp β57 that differs from the
uncharged Ala β57 found in non-PV associated
DRB1*1401 and *1404. Also, at positions β70 and β71,
DQB1*0503 does not contain negatively charged residues
identified in DRB1*0402 that are critical for binding of
self-antigens in DR4 PV patients. Instead, these positions
were replaced by two small neutral hydrophobic residues
(Gly β70 and Ala β71), suggesting that DRB1*0402 and
Table 1: Sequence and structural similarity between the eight (DRB1*0402, *0404, *0406, *1401, *1404, *1405, DQB1*0202, and *0503) 
MHC structural models and their corresponding template structures (1D5Z: DRB1*0401, 1S9V: DQB1*0201, 1UVQ: DQB1*0602). 
Positives represent a measure of sequence similarity, accounting for identical and conservatively substituted residues. Root mean 
square deviations (RMSD) values in Å are shown for the Cα atoms of both MHC chains and for the residues comprising the different 
peptide-binding pockets.
Allele Template Sequence 
Identity
Positives Cα RMSD (Å)
α & β 
chains
Pockets
P1 P4 P6 P7 P9
DRB1*0402 1D5Z 97.9% 99.0% 0.35 0.12 0.06 0.07 0.10 0.09
DRB1*0404 1D5Z 99.0% 99.5% 0.31 0.15 0.10 0.06 0.07 0.18
DRB1*0406 1D5Z 97.9% 98.4% 0.32 0.11 0.15 0.07 0.11 0.22
DRB1*1401 1D5Z 94.1% 97.3% 0.25 0.11 0.09 0.02 0.09 0.18
DRB1*1404 1D5Z 85.8% 89.5% 0.29 0.12 0.10 0.02 0.06 0.22
DRB1*1405 1D5Z 81.0% 83.2% 0.24 0.11 0.07 0.02 0.08 0.07
DQB1*0202 1S9V 98.0% 99.0% 0.57 0.16 0.09 0.04 0.15 0.05
DQB1*0503 1UVQ 93.0% 96.0% 0.39 0.03 0.07 0.01 0.10 0.06Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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DQB1*0503 may recognize different sets of PV epitopes
under the influence of a different balance of intermolecu-
lar forces. Positions β70 and β74 show charge reversal, in
the non-PV associated DRB1*1401, *1404 and *1405
alleles while the negative charge at β71 alone is conserved,
compared to DRB1*0402, making pocket 4 the single
dominant factor discriminating between PV non-associa-
tion and susceptibility.
Allele comparisons – PV protective and susceptible alleles
Differences in the amino acid sequences are observed at
residue β86 of pocket 1, residue β70, β71 of pocket 4, res-
idues β28, β30, β47, β71 of pocket 7 and residues β37,
β57 of pocket 9. Both protective alleles (DQB1*0201 and
DQB1*0202) do not contain negatively charged residues
at position β70 (pocket 4) and β71 (pocket 7). Instead,
these positions were replaced by two large and positively
charged amino acids (Arg β70 and Lys β71). The func-
tional specificities of PV protective and susceptible alleles
are also affected by clear structural differences in the Cα
positions of both α and β chains (Cα RMSD > 0.57Å)
indicating that any differences in peptide discrimination
between the alleles is due to a combination of both the
backbone conformation as well as the size and nature of
the side chains of the pocket residues.
Epitope comparisons – HLA DR4 PV
Eight previously identified stimulatory Dsg3 epitopes
(Dsg3 191–205, Dsg3 206–220, Dsg3 252–266, Dsg3
342–356, Dsg3 380–394, Dsg3 763–777, Dsg3 810–824
and Dsg3 963–977) for DRB1*0402 were docked into the
binding groove of all DR4 (DRB1*0401, *0402, *0404,
Multiple sequence alignment of the MHC DR and DQ alleles β chain Figure 1
Multiple sequence alignment of the MHC DR and DQ alleles β chain. Pocket residues are shaded in black.Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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*0406) alleles investigated in this study. Analysis of these
Dsg3 peptide-bound alleles revealed that only one pep-
tide conformation can fit perfectly into the binding cleft of
DRB1*0402, and atomic clashes of these Dsg3 peptides
are obtained for all other DR4 subtypes investigated in
this study. Notably, two epitopes (Dsg3 342–356 and
Dsg3 810–824) have small residues (Ser/Cys) in pocket 1,
suggesting that large anchor residues may play a critical
role for high affinity binding in DR4 PV molecules, an
observation previously documented for influenza-associ-
ated I-Ad allele of mice [31]. This finding provides support
to the evidence that DRB1*0402 is associated with PV
whereas other DR4 subtypes are non-associated, with the
exception of DRB1*0406 that is reported to be associated
in the Japanese population [32]. As such, there is a possi-
bility of the existence of other peptides relevant in the Jap-
anese populations that bind to *0406 but are yet to be
determined.
Epitope comparisons – HLA DR6 PV
Dsg3 96–112, a recently identified epitope in DR6 PV
patients [28], fits perfectly into the binding groove of
DQB1*0503 with two identified core sequences at resi-
dues 101–109 and residues 102–110. The identified 101–
109 core has four intermolecular hydrogen bonds com-
pared to seven intermolecular hydrogen bonds in the core
of 102–110. Perfect fitting of Dsg3 206–220, Dsg3 252–
266, Dsg3 342–356, Dsg3 810–824 and Dsg3 963–977
into the binding groove of DQB1*0503 is also obtained.
Atomic clashes are obtained for Dsg3 191–205, Dsg3
380–394 and Dsg3 763–777 as well as all DR6 alleles
investigated in this study. The proportion of DRB1*1401,
*1404 and *1405 has been reported to be increased in PV
probably due to linkage disequilibrium. The lack of bind-
ing of all stimulatory peptides investigated in this study to
these alleles indicates that the HLA association in DR6 PV
patients is more likely at the DQB1 locus (DQB1*0503
allele) and not the linked DRB1 loci (DRB1*1401, *1404
and *1405). Our data supports the notion that the
reported associations of this disease with DRB1*1401,
*1404, *1405 are due to linkage disequilibrium with the
true disease associated allele (DQB1*0503).
Epitope comparisons – PV susceptibility Alleles
Our docking simulations reveal strong evidence that
DRB1*0402 and DQB1*0503 can bind to different sets of
PV epitopes by recognizing different core peptide
sequences in the binding groove (Table 2). Three PV
epitopes (Dsg3 191–205, Dsg3 380–394 and Dsg3 763–
77) can only bind to DRB1*0402, four PV epitopes (Dsg3
206–220, Dsg3 252–266, Dsg3 342–356 and Dsg3 810–
824) can bind to both alleles with different core peptide
sequences, one PV epitope (Dsg3 963–977) can bind to
both alleles with the same core peptide sequence, and one
PV epitope (Dsg3 96–112) can only bind to DQB1*0503.
DRB1*0402 and DQB1*0503 may recognize the same
Dsg3 epitope at two unique sets of core sequences (which
may be in close proximity) within the epitope itself. These
findings are completely in accord with experimental data
[28].
Epitope comparisons – PV protective alleles
Our simulation results indicate that DQB1*0201 and
DQB1*0202 can bind to multiple core sequences for the
majority of PV epitopes investigated in this study.
DQB1*0201 can bind one epitope (Dsg3 963–977) at
two core regions, one epitope (Dsg3 206–220) at three
core regions, three epitopes (Dsg3 191–205, 252–266 and
342–356) at four core regions, and two epitopes (Dsg3
96–112 and 810–824) at five core regions. DQB1*0202
can bind two epitopes (Dsg3 96–112 and 963–977) at
three core regions, two epitopes (Dsg3 342–356 and 810–
824) at four core regions and one epitope (Dsg3 252–
266) at five core regions. In contrast, the majority of PV
epitopes (with the exception of Dsg3 96–112 and 252–
266) can bind to PV susceptible alleles DRB1*0402 and
DQB1*0503 at a single core. This finding lends support to
the hypothesis that the protective alleles DQB1*0201,
Table 2: Preferred core residues for PV associated alleles. Best fitting nonameric core residues in the binding groove are underlined.
No. Residues Allele Core peptide sequences No. Residues Allele Core peptide sequences
I 96–112 DRB1*0402 - V 342–356 DRB1*0402 SVKLSIAVKNKAEFH
DQB1*0503 PFGIFVVDKNTGDINIT DQB1*0503 SVKLSIAVKNKAEFH
PFGIFVVDKNTGDINIT VI 380–394 DRB1*0402 GIAFRPASKTFTVQK
II 191–205 DRB1*0402 NSKIAFKIVSQEPAG DQB1*0503 ---
DQB1*0503 --- VII 763–777 DRB1*0402 SGTMRTRHSTGGTNK
III 206–220 DRB1*0402 TPMFLLSRNTGEVRT DQB1*0503 ---
DQB1*0503 TPMFLLSRNTGEVRT VIII 810–824 DRB1*0402 NDCLLIYDNEGADAT
IV 252–266 DRB1*0402 ECNIKVKDVNDNFPM DQB1*0503 NDCLLIYDNEGADAT
DQB1*0503 ECNIKVKDVNDNFPM IX 963–977 DRB1*0402 ERVICPISSVPGNLA
ECNIKVKDVNDNFPM DQB1*0503 ERVICPISSVPGNLAImmunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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*0202 may be capable of binding to most peptides with
greater affinity than PV susceptible alleles, allowing for
efficient deletion of autoreactive T cells [33].
Role of flanking residues in peptide selection
Our data demonstrates that the conformations of flanking
peptide residues that extend beyond the binding groove
are critical to peptide selection in MHC class II alleles. The
core sequences of Dsg3 963–977 fit perfectly within the
binding grooves of non-associated alleles DRB1*0401,
*0404, and *1404 but poor contacts to the respective alle-
les at Phe α50 are obtained when the conformation of the
N-terminal flanking residue Ile4 is taken into account.
These results suggest that binding is determined by both
the core and flanking segments while considering the
overall interactions between each peptide and the respec-
tive alleles.
Sequence motifs
Sequence-based epitope prediction relies on the identifi-
cation of sequence motifs from available experimental
data. The correlation of core peptide residues with bind-
ing motifs previously defined by Veldman et al. [28] and
Sinha et al. (unpublished results) is shown in Table 3, to
understand to what extent sequence-based approaches
will be valid with specific reference to PV. The sequence
conservation observed here is too low to warrant the gen-
eration of a consensus sequence pattern.
Peptide VII (Dsg3 763–777) agrees well with the motifs
from Veldman et al. [28] and Sinha et al. (unpublished
results), while all other peptides show low to moderate
compliance. Of the four positions compared, peptide IV
(Dsg3 252–266) shows agreement only at position p6.
For Dsg3 342–356 peptide, the core nonamer identified
by our models is 346–354, which is register-shifted by one
residue from the core of 347–355 reported by Veldman et
al. [28], and 345–353 identified by Sinha et al. (unpub-
lished results), for the binding groove of *0402. This shift
is critical as residues p1 and p4 identified by us do not fit
well into both binding motifs. Our modeling studies sug-
gest that peptide position p4 need not be positively
charged as indicated by Veldman et al. [28], supporting
the existence of a more degenerate motif by Sinha et al.
(unpublished results) at this position. In addition, p1 also
appears to be more degenerate than previously suggested
[28], showing a preference for hydrophobic and large res-
idues but can accommodate residues of other sizes as well.
Hence for generating sequence patterns to design peptides
for vaccine design, structural information is important
[34] and the exact peptide in the binding groove identi-
fied by our docking protocol will be most useful here.
Disease progression in PV
T cell response to a number of epitopes among PV patients
has been reported in several studies [2,8,26,29,30]. There
may be disease heterogeneity, meaning that clinically sim-
ilar but distinct phenotypes could operate by alternate
pathways, each with a different initial immunodominant
epitope(s). The differential T cell reactivities among indi-
vidual patients to individual peptides may also be a func-
tion of the disease stage or severity and correlate with
mechanisms of disease progression. While there may be a
limited set of epitopes present in patients in the early
stages of the disease, epitope spreading can occur during
disease progression, resulting in reactivity to previously
innocuous epitopes. In addition, reactivities to multiple
epitopes within individual patients were detected in two
cases (Dsg3 191–205 and 342–356 for PV107; Dsg3 191–
205, 810–824 and 963–977 for PV117). Autoantibodies
against desmoglein 1 have also been reported in severe
disease [35]. One other incidence of multiple T cell reac-
tivities within a PV patient has been previously reported
[29]. These findings, together with our simulation results,
Table 3: Comparison of core peptides (numbering according to Table 2) from structural docking in the different binding pockets with 
the sequence-based binding motifs. '+' indicates compliance of amino acid residues within the core (bold underlined) with the 
respective binding motifs defined by the groups of a Veldman [28] and bSinha [2, unpublished results].
No. Residues Peptide Sequence and positions in the
 bound conformation for DRB1*0402
Core peptide residue positions
 as defined by binding motifs
p1 p4 p6 p9
1 2 3 4 5 6 7 8 9 Va Sb VSVSVS
II 191–205 NSKIA F K I V S Q E P A G+ + + +
III 206–220 TPM F L L S R N T G E VRT + + + +
IV 252–266 ECNI K V K D V N D N F PM + +
V 342–356 SVKL S I A V K N K A E F H +++ +
VI 380–394 GIA F R P A S K T F T VQK + + + +
VII 763–777 SGT M R T R H S T G G T N K + + ++++ +
VIII 810–824 ND C L L I Y D N E G ADAT + + +
IX 963–977 ERVICP I S S V P G N L A ++ + +Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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lend further credence to the hypothesis that no single
epitope is responsible for both disease initiation and
propagation and are consistent with the expected and
observed ability to generate multiple pMHC complexes
from a single target autoantigen.
Conclusion
Docking simulations at the binding site of PV associated
and non-associated DR and DQ alleles have been per-
formed to analyze the structural aspects of binding and
allele-specificity for nine previously identified Dsg3
epitopes. To represent the possibility that any core peptide
sequences can be recognized by the binding groove of
MHC class II alleles, a sliding window was applied to gen-
erate all possible combinations of core nonamer peptides
from each Dsg3 peptide. This method can eliminate any
bias in selecting core peptides based on sequence patterns
alone.
We have found the existence of best-fit core residues at dif-
ferent positions of each peptide (excepting Dsg3 96–112)
into the binding groove of DRB1*0402 with no observed
atomic clash penalties or bad contacts. In contrast, atomic
clashes are experienced in all other PV non-associated
DR4 alleles. This discrimination further establishes the
crucial role that DRB1*0402 plays in selecting specific
self-peptides in DR4 PV. In addition, we found that
DRB1*0402 and DQB1*0503 do not necessarily share
the same core residues. It is possible that DRB1*0402,
DQB1*0503 and all other PV non-associated alleles may
have different sets of binding specificities. Our studies
also indicate that perfect fitting of the core nonameric
peptide residues within the binding groove of MHC class
II alleles may not guarantee perfect fitting of the entire
peptide, and flanking residues outside the binding groove
may play a critical part in peptide selection. Such binding
interactions suggest that longer peptides extending out of
the binding groove of MHC class II alleles must be taken
into account in the generation of HLA class II binding
motifs and for vaccine design.
The comparison of core peptide residues with binding
motifs previously defined by Veldman et al. [28] and
Sinha et al. (unpublished results) indicates that sequence-
based methods are currently insufficient for the design of
PV epitopes as there are both register shifts in the sug-
gested motifs as well as polymorphism observed in the
core residues in the binding groove. More experimental
data are necessary for the definition of DR4 and DR6 PV
specific binding motifs.
The methodology presented here may serve as a general
method suitable for finding allelic specific peptides, appli-
cable to the design of both sub-type specific vaccines as
well as promiscuous peptide epitopes. In particular, this
approach is useful in situations where there is insufficient
data for training sequence-based predictive models. In the
context of PV, this approach provides a means for discrim-
inating between peptide binders and non-binders for a
number of PV implicated alleles where training data is
deficient. Our results support the hypothesis [33] that the
alleles DQB1*0201 and *0202 play a protective role by
binding Dsg3 peptides with greater affinity than the sus-
ceptible alleles, facilitating efficient deletion of autoreac-
tive T cells. With increasing evidence indicating that no
single epitope may be responsible for both disease initia-
tion and propagation in PV, it is valuable to identify all
Dsg3 peptides that bind to the PV susceptible alleles. Spe-
cifically, the identification of peptides that bind to both
DRB1*0402 and DQB1*0503 are of great importance as
these peptides may serve as targets for epitope-based ther-
apeutic vaccination of both DR4 and DR6 PV patients.
Table 4: HLA class II haplotypes of PV patients (PV) and controls (CR). Typing was performed at the Rogosin Institute, New York 
Presbyterian Hospital, NY.
Subject Sex Age DRB1 DQB1 DQA
PV104 F 64 *0402, *0403 *0302, *0304 *03011
PV105 F 73 *1404, *0102 *0503, *0501 *01041, *0101
PV107 F 70 *0402, *0102 *0302, *0501 *03011, *0101
PV108 F 52 *0402, *0404 *0302, *0304 *03011, *0303
PV112 F 57 *0402, *1101 *0302, *0301 *03011, *0505
PV114 M 50 *0402, *1401 *0503, *0302 *03011, *01041
PV115 F 34 *0402, *0701 *0302, *0202 *03011, *0201
PV117 M 44 *0402, *0403 *0302, *0305 *03011
PV118 M 62 *0402, *1302 *0601, *0402 *0102, *0303
CR101 F 58 *0402, *0701 *0202, *0302 *0201, *0301
CR102 M 81 *0402, *1101 *0301, *0302 *0501-05, *0301Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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Future work will include autoantigens from Dsg1, the
main causative agent for pemphigus foliaceus and
reported in severe cases of PV.
Materials and methods
Template search
In this study, ten PV associated, closely related non-asso-
ciated and protective MHC class II alleles DRB1*0401,
*0402, *0404, *0406, *1401, *1404, *1405,
DQB1*0201, *0202, and *0503 were selected for analy-
sis. MHC sequence data were obtained from IMGT-HLA
http://www.ebi.ac.uk/imgt/hla/[36] database. The α
chain of all DR alleles investigated in this study is the
DRA1*0101 sequence, with the β chain from the allele
sub-type. To identify potential structural templates availa-
ble in the Protein Data Bank (PDB) [37] for model build-
ing, a sequence similarity search was performed using PSI-
BLAST [38] running on the servers at NCBI http://
www.ncbi.nlm.nih.gov/blast/ and the highest quality
templates were selected among the returned results.
Among these, the crystal structures of HLA-DR4 (PDB
code 1D5Z) and HLA-DQ2 (PDB code 1S9V) were
adopted as the structures of DRB1*0401 and DQB1*0201
respectively (100% sequence identity). The crystal struc-
tures of DRB1*0401 (PDB code 1D5Z), DQB1*0602
(PDB code 1UVQ) and DQB1*0201 (PDB code 1S9V)
were selected as templates for all other DR subtypes,
DQB1*0503 and DQB1*0202 respectively (Table 1).
Model building
The program MODELLER [39] was employed for compar-
ative modeling of both DRB1 (*0402, *0404, *0406,
*1401, *1404, *1405) and DQB1 (*0202, *0503) sub-
types. The models are constructed by optimally satisfying
spatial constraints obtained from the alignment of the
template structure with the target sequence and from the
CHARMM-22 force field [40]. The initial model was
refined by assigning the rotameric states of essential side
chains according to the corresponding crystal structure,
followed by a short energy minimization [41] from the
program Internal Coordinates Mechanics (ICM; Molsoft
LLC, San Diego, CA) [42].
Patient recruitment and groupings
Patients and controls were recruited from the Dermatol-
ogy clinics at New York Presbyterian Hospital (Cornell
Campus, New York, NY). HLA typing was performed at
the Rogosin Institute, New York Presbyterian Hospital,
NY. Controls were without disease and were HLA types
DRB1*0402 (n = 1), or DRB1*0402 and DQB1*0503 (n
= 1); while PV patients typed as DRB1*0402 (7/9),
DRB1*0402 and DQB1*0503 (1/9), or DQB1*0503 (1/
9) (Table 4).
Peptide set
Nine previously identified epitopes Dsg3 96–112, 191–
205, Dsg3 206–220, Dsg3 252–266, Dsg3 342–356, Dsg3
380–394, Dsg3 763–777, Dsg3 810–824 and Dsg3 963–
977 that elicited primary proliferative T cell response in
PV patients [2,8,26,29,30] were selected for modeling
studies. T cell response to eight of these peptides (Dsg3
191–205, Dsg3 206–220, Dsg3 252–266, Dsg3 342–356,
Dsg3 380–394, Dsg3 763–777, Dsg3 810–824 and Dsg3
963–977) has been reported in patients carrying
DRB1*0402. Dsg3 96–112 has been reported to elicit T
cell response in patients with DQB1*0503 but lacking
DRB1*0402 [28]. Of these Dsg3 191–205, Dsg3 342–
356, Dsg3 810–824 and Dsg3 963–977 were shown to
directly bind to the DRB1*0402 receptor by competitive
binding assays (Sinha et al., unpublished results). Briefly,
soluble HLA DRA1*0101/DRB1*0402 were purified by
DR-specific affinity chromatography and incubated with
different concentrations of experimental peptides (0–40
µM) in the presence of biotinylated class II-associated
invariant-chain peptide (CLIP) (1 µM) for 2 hours. The
MHC-peptide complexes were then captured on a 96-well
plate coated with anti-HLA-DR (L243) (BD Pharmingen,
San Diego, CA). The CLIP bound to the MHC molecules
was directly assayed using Europium (Eu)-labeled strepta-
vidin (Perkin Elmer, Boston, MA). The relative binding of
peptides was subsequently determined by measuring the
displacement of the CLIP at different peptide concentra-
tions.
Peptide docking
Analysis of binding motifs http://www.syfpeithi.de[43]
and available crystal structures suggested a core region of
nine amino acids as essential for binding. Based on this
observation, a sliding window input of size nine (Figure
2) is applied to generate all combinations of nonameric
core peptide residues to be modeled into the binding
groove of each allele. Each core peptide fragment is
docked into the binding groove in a three-step protocol
described in an earlier study [27]. In brief, docking of core
peptide residues is performed as follows: (i) core peptide
fragments at the ends of the binding groove is docked
using ICM biased Monte Carlo procedure, followed by (ii)
loop closure of peptide core residues by satisfaction of
Sliding window of width 9 applied to identify core residues of  Dsg3 963–977 to be modeled into binding groove Figure 2
Sliding window of width 9 applied to identify core residues of 
Dsg3 963–977 to be modeled into binding groove.Immunome Research 2006, 2:1 http://www.immunome-research.com/content/2/1/1
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spatial constraints, and finally (iii) refinement of the
backbone and side-chains of peptide core residues as well
as atomic clash regions at receptor. Next, flanking residues
are extended from the core peptide residues using ICM
biased Monte Carlo procedure. The adopted empirical
scoring function [44,45] takes into account continuum
and discrete electrostatics, and hydrophobic and entropy
loss [45,46]. This methodology allows rapid and accurate
docking of peptides with an average computing time of
approximately 18 minutes for the complete modeling of
each peptide on a 4-CPU SGI Origin 3200 workstation.
For each ligand, the best solution is obtained based on the
following criteria: pattern of hydrogen bonding to the
MHC molecule, pattern of hydrophobic burial of peptide
side chains, and the absence of atomic clashes or repulsive
contacts.
Definition of contact residues
In this study, MHC-peptide residues were considered to
be in contact if at least one pair of their non-hydrogen
("heavy") atoms was found to be within 4.00Å radius
[47]. Intra-peptide interactions and intra-MHC interac-
tions were not considered as they have minor influence
on peptide/protein backbone structure. Any atom in the
peptide and any atom in the MHC were considered to be
experiencing atomic clash if their separation is below
2.00Å [48] for non-hydrogen atoms and below 1.60Å for
atoms participating in hydrogen bonds [49,50].
Definition of binding pocket for MHC Class II alleles
Interactions between side-chains of bound peptide lig-
ands and polymorphic cavities (or anchor "pockets") in
the binding site of MHC class II alleles are important in
determining the peptide binding affinity and sequence
specificity of MHC molecules and are defined according
to the work of Stern et al. [51,52].
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